Several large-scale randomized-controlled trials (RCTs) of SGLT2 inhibitors have demonstrated substantial benefits in cardiovascular and renal outcomes among subjects with T2D [1], and SGLT2 inhibitors have recently shown benefits in renal and heart failure even in individuals without diabetes [2,3,4]. Here, SLC5A2 is linked to type 2 diabetes mellitus.